Released Mar 31, 2022, after the close
10-K filed Mar 31, 2022, 90 days after period end · 0001390478-22-000006
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$0.00$0.00 derived−100.0% vs Q4 2020no prior Q3 2021 on file
Net Income-$6.60M-$6.60M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$11,619,000N/M
Operating Cash Flowderived-$4,976,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018dderived from reported figures |
|---|---|---|---|---|
| Revenue | $0.00 | $1.90M | — | — |
| Net Income | -$6.60M | -$3.72M | -$7.42M | -$13.32M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR